BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by Doliver Advisors LP

Doliver Advisors LP reduced its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 18.7% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 304,328 shares of the biotechnology company’s stock after selling 70,000 shares during the quarter. BioCryst Pharmaceuticals makes up approximately 0.5% of Doliver Advisors LP’s holdings, making the stock its 28th biggest position. Doliver Advisors LP owned approximately 0.12% of BioCryst Pharmaceuticals worth $2,535,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Bank of America Corp DE increased its stake in BioCryst Pharmaceuticals by 231.6% in the 1st quarter. Bank of America Corp DE now owns 5,091,765 shares of the biotechnology company’s stock valued at $48,474,000 after buying an additional 3,556,208 shares during the last quarter. Pacer Advisors Inc. bought a new position in shares of BioCryst Pharmaceuticals in the 1st quarter valued at about $14,880,000. ADAR1 Capital Management LLC bought a new position in shares of BioCryst Pharmaceuticals in the 2nd quarter valued at about $1,330,000. Wedge Capital Management L L P NC acquired a new stake in shares of BioCryst Pharmaceuticals in the second quarter valued at about $3,808,000. Finally, Perceptive Advisors LLC increased its position in shares of BioCryst Pharmaceuticals by 135.1% in the first quarter. Perceptive Advisors LLC now owns 7,434,033 shares of the biotechnology company’s stock valued at $70,772,000 after acquiring an additional 4,271,504 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX stock traded down $0.21 during midday trading on Thursday, hitting $8.12. 5,785,302 shares of the company were exchanged, compared to its average volume of 4,882,365. BioCryst Pharmaceuticals, Inc. has a 52 week low of $6.00 and a 52 week high of $11.22. The firm has a market capitalization of $2.07 billion, a P/E ratio of -5.41 and a beta of 0.57. The firm’s 50 day moving average price is $9.28 and its two-hundred day moving average price is $9.25.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The firm had revenue of $218.25 million for the quarter, compared to analysts’ expectations of $183.28 million. During the same period in the prior year, the firm earned $0.15 EPS. The business’s revenue was up 33.6% on a year-over-year basis. Analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.25 EPS for the current year.

Analyst Ratings Changes

BCRX has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $32.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Wall Street Zen downgraded BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 29th. Weiss Ratings cut shares of BioCryst Pharmaceuticals from a “hold (c)” rating to a “sell (d-)” rating in a research note on Tuesday, September 22nd. Royal Bank Of Canada lowered shares of BioCryst Pharmaceuticals from an “outperform” rating to a “sector perform” rating and dropped their price target for the stock from $13.00 to $11.00 in a research report on Thursday, September 10th. Finally, Wedbush cut their price target on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Seven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.50.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes oral medicines for rare diseases. The company focuses on small-molecule therapies designed to address diseases with significant unmet medical needs, including hereditary angioedema and complement-mediated disorders.

BioCryst’s primary commercial product is Orladeyo (berotralstat), an oral plasma kallikrein inhibitor used to prevent attacks of hereditary angioedema in adults and pediatric patients.